Citeline：2025年因编辑、细胞治疗与RNA技术前沿报告行业现状报告（英文版）

An increase in the number of gene therapy programs was seen at all stages of pipeline development, The number of gene therapies currently in pre-registration remains the same as Q1 2025, thoughthe assets have changed slightly, including the addition of Orchard Therapeutics and FondazioneTelethon's OTL-103 now filed in both the Us and Eu, and Belief BioMed recently attaining approvalfor BBM-H901